Concepedia

Publication | Open Access

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

DOIFull Paper Access

134

Citations

22

References

2021

Year

Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani, David R. D’Adamo, Gursel Aktan, Michaela L. Tsai, Ruth O’Regan, Peter A. Kaufman, Sharon Wilks, Eleni Andreopoulou,
Clinical Cancer Research

Abstract

Eribulin plus pembrolizumab was generally well tolerated and showed promising antitumor activity in mTNBC. Efficacy outcomes appeared influenced by line of therapy and PD-L1 status.

References

YearCitations

Page 1